Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 13, 2007

bioMérieux Contracts Sloning to Provide Gene Mutant Library for Use in Diagnostics Program

  • Sloning BioTechnology will carry out a feasibility study together with bioMérieux to generate a large number of gene variants of a particular enzyme that will be used in diagnostic applications.

    Sloning will use its Slonomics™ gene synthesis technology to provide a gene library with a full set of ratio-controlled mutants. The successful completion of the study will enable bioMérieux to identify an enzyme with significantly enhanced characteristics, according to the companies.

    “We are very excited about this collaboration. It gives Sloning the opportunity to demonstrate the capabilities of our enabling technology in the field of protein engineering and synthetic biology and in this particular case with a significant commercial impact to our customer,” states Heinz Schwer, Sloning’s CEO.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »